LL-37: Antimicrobial Peptide and Immune Modulator

LL-37 is the only member of the cathelicidin family of antimicrobial peptides expressed in humans. Named for its 37 amino acids and the leucine-leucine dipeptide at its N-terminus, LL-37 serves as a front-line defender against microbial invasion while simultaneously modulating the adaptive immune response, promoting tissue repair, and acting as a signaling molecule with roles in cancer biology and autoimmunity. Its dual role as both a direct antimicrobial and an immune regulator makes it one of the most pharmacologically interesting endogenous peptides.

Antimicrobial Mechanisms

LL-37 kills bacteria through membrane disruption. The peptide adopts an amphipathic alpha-helical conformation when it contacts bacterial membranes, inserting into the lipid bilayer and forming pores that cause ion leakage and cell death. This physical disruption mechanism — rather than targeting specific bacterial proteins — makes LL-37 active against a remarkably broad spectrum: gram-positive bacteria, gram-negative bacteria, mycobacteria, fungi, and enveloped viruses.

Critically, bacteria find it difficult to develop resistance to membrane-disrupting peptides because doing so would require fundamental changes to their lipid composition. This makes LL-37 a candidate for addressing antibiotic-resistant organisms.

Immune Modulation Beyond Killing

LL-37 does more than kill microbes directly. It acts as a chemoattractant, recruiting neutrophils, monocytes, and T cells to sites of infection. It promotes dendritic cell maturation and antigen presentation, bridging innate and adaptive immunity. In macrophages, LL-37 suppresses LPS-driven TNF-alpha production while enhancing clearance of infected cells.

The peptide also neutralizes LPS (lipopolysaccharide), the gram-negative bacterial toxin that drives septic shock. This anti-endotoxin activity suggests a role in preventing inflammatory cascades during gram-negative infections.

Wound Healing and Tissue Repair

LL-37 stimulates keratinocyte migration and proliferation — key steps in wound closure. It promotes angiogenesis through VEGF upregulation and activates fibroblasts to increase collagen production. In diabetic wound models, LL-37 treatment dramatically accelerates closure of chronic, non-healing wounds.

This wound-healing capacity has made LL-37-derived peptides attractive for dermatological applications. Several companies have developed modified LL-37 analogs for topical wound care.

Role in Skin Diseases

LL-37 levels are elevated in psoriasis lesions and may contribute to the inflammatory loop that drives the disease — LL-37 forms complexes with self-DNA, activating plasmacytoid dendritic cells via TLR9 and triggering interferon production. This makes it a contributor to, not just a defender against, inflammatory skin disease.

Conversely, patients with atopic dermatitis (eczema) have impaired LL-37 expression, contributing to their increased susceptibility to skin infections, particularly Staphylococcus aureus.

Research and Therapeutic Development

Multiple LL-37 analogs and derivatives are in clinical development. GN-4 and other modified analogs show improved stability and reduced toxicity at therapeutic doses. Applications being developed include topical wound care, antibiotic-resistant infection treatment, and adjuvant immunotherapy for cancer.

Vitamin D is a natural inducer of LL-37 production. Vitamin D deficiency is associated with low LL-37 expression, which may partly explain the link between vitamin D status and infection susceptibility.

Dosing and Access

LL-37 itself is too toxic for systemic administration at antimicrobial doses due to hemolytic activity (destroying red blood cells). Clinical development focuses on topical application and optimized analogs with improved safety profiles. Native LL-37 is available as a research peptide but is not validated for human use.

FAQ

Why is LL-37 important for vitamin D? Vitamin D directly upregulates the cathelicidin gene (CAMP) that encodes LL-37. Optimal vitamin D status (above 40 ng/mL) supports robust LL-37 production, which may explain much of vitamin D's infection-fighting benefit.

Can LL-37 treat MRSA? In vitro, LL-37 kills MRSA effectively. The challenge is developing a formulation that can deliver effective concentrations to infected tissue without systemic toxicity. Topical formulations show promise for skin MRSA infections.

Is LL-37 involved in COVID-19? LL-37 has antiviral activity against enveloped viruses and was studied in the context of COVID-19. Observational studies found lower LL-37 levels in severe COVID cases, and vitamin D supplementation to raise LL-37 was proposed as a protective strategy.

Track your supplements in Optimize.